1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends

Global Infectious Diseases Therapeutics Market—Influenza, RSV, Chlamydia, and Gonorrhoea

  • February 2014
  • 137 pages
  • Frost & Sullivan
Report ID: 2039413

Summary

Table of Contents

Persistent Unmet Need for Treatment Fuels Novel Antiviral/Antibacterial Drug Development

RSV Antivirals
• Ribavirin, the only approved antiviral directed at the human respiratory syncytial virus (RSV), is modestly effective. Variable response, development of resistance and viral breakthrough, along with poor tolerability and suboptimal dosing regimens, however, do not support the regular use of ribavirin.
• Successful commercialisation of next-generation antibodies and the launch of cheaper biosimilar versions of Synagis are likely to result in improved immunoprophylactic therapy for RSV.
• Clinical trials investigating the development of vaccines for the prevention of RSV are ongoing. Market participants strive to overcome challenges associated with incomplete immune response in very naive infants, and strain variability.

Influenza Antivirals and Vaccines
• Antivirals, particularly second and third-generation neuraminidase inhibitors, are quite effective in the treatment of influenza. However, the development of resistance to antivirals remains a key challenge.
• Egg-based vaccines, for the prevention of both seasonal and pandemic influenza, are currently in use.
• The imminent arrival of novel innovative vaccine technologies, in terms of adjuvants, carriers, and drug delivery mechanisms, has resulted in significant sophistication levels in egg-based vaccines for the prevention of seasonal and pandemic influenza.
• Nevertheless, several newer classes of antivirals, cell-based vaccines, and non-invasive drug delivery systems are currently being investigated to improve efficacy and patient compliance.

Chlamydia Antibacterials
• The currently available antibacterials directed against uncomplicated urogenital chlamydia are quite effective and offer a therapeutic cure rate of over xx%.
• As the chlamydia trachomatis infection is predominantly asymptomatic, diagnosis of the disease still remains a key challenge. Hence, the majority of the clinical development activity is directed towards the assessment and testing of the disease.
• Clinical pipelines are very dry with few new compounds being investigated for the treatment of chlamydia. Minimal research and development (R&D) activity is carried out in this market segment.

Gonorrhoea Antibacterials
• The currently available antibacterials directed against Neisseria gonorrhoea are moderately effective. The development of resistance to almost every recommended antibiotic for the treatment of gonorrhoea makes treatment complicated.
• Increased assessment of combination therapies and the investigation of newer classes of antibiotics are likely to contribute to significant cure rates of over xx%.
• Cephalosporins, such as ceftriaxone and cefixime, are currently looked upon as the last line of defence for gonorrhoea, despite a few recently reported cases of resistance to these antibiotics.
• Currently, Cempra Inc. is evaluating solithromycin in phase I/II trials for the treatment of bacterial pneumonia, uncomplicated urogenital gonorrhoea, and other sexually transmitted infections (STIs)

Methodology and Scope

• This research service focuses on antibiotic/antibacterial therapeutics for the treatment of infection by blood-borne (sexually transmitted) bacteria, which include chlamydia trachomatis and Neisseria gonorrhoea as well as antiviral therapeutics for infection by vector borne pathogens such as the influenza virus and the human respiratory syncytial virus (RSV).
• A product and pipeline assessment is provided for marketed and investigational products and combination regimens for the treatment of chlamydia trachomatis, Neisseria gonorrhoea, influenza and RSV infections. Segmentation by drug class is provided along with additional supporting information, such as clinical trial timelines, results and epidemiology.
• The information contained in this research service was derived from published sources, including the following: Disease organisation web sites; public health organisation web sites; company publications including annual reports, US Securities and Exchange Commission (SEC) filings, and press releases; government public sources; and published articles in scientific journals.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers
Infectious Disease Drugs: The Chinese Market

Infectious Disease Drugs: The Chinese Market

  • $ 6650
  • Industry report
  • March 2017
  • by BCC Research

Use this report to: - Assess market dynamics of Chinese market for both communicable and - non-communicable infectious disease drugs, their opportunities and restraints. - Evaluate Chinese drug market ...

Global Respiratory Complications Therapeutics Market to 2022 - Innovative Pneumonia and Pulmonary Arterial Hypertension Therapies Dominate Varied Disease Market

Global Respiratory Complications Therapeutics Market to 2022 - Innovative Pneumonia and Pulmonary Arterial Hypertension Therapies Dominate Varied Disease Market

  • $ 4995
  • Industry report
  • March 2017
  • by GBI Research

Global Respiratory Complications Therapeutics Market to 2022 - Innovative Pneumonia and Pulmonary Arterial Hypertension Therapies Dominate Varied Disease Market Summary Respiratory complications are a ...

Opportunity in the Indian Anti-Infective Pharmaceuticals Market - 2017

Opportunity in the Indian Anti-Infective Pharmaceuticals Market - 2017

  • $ 4500
  • Industry report
  • March 2017
  • by Feedback Business Consulting

This report provides insight into the current market scenario, structure and practices. In depth market scenario includes: - Current market size estimate - Revenues by players - Top 5 Companies - Market ...


Download Unlimited Documents from Trusted Public Sources

Anti-Infective Market in the US

  • May 2017
    19 pages
  • Anti-Infective  

  • United States  

View report >

Pharmaceutical Demand Statistics in India

  • May 2017
    32 pages
  • Pharmaceutical  

    Therapy  

  • India  

    Asia  

View report >

Anti-Infective Market

  • May 2017
  • Anti-Infective  

  • New Zealand  

    Australia  

    South Korea  

View report >

Anti-infective Market

2 months ago

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.